Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796154 | 0.84 | EGFR (0.41) | CYP19A1NPY2RCA12CA1CA2 | |
| SCHEMBL4801050 | 0.83 | RAPGEF4 (0.40) | RAPGEF4CA12CA1CA2CA9 | |
| SCHEMBL989351 | 0.83 | NPY2R (0.44) | NPY2RCA12CA1CA2CA9 | |
| SCHEMBL21797170 | 0.81 | TLR9 (0.41) | RAPGEF4CA12CA1CA2CA9 | |
| SCHEMBL5741463 | 0.77 | KMT2A (0.40) | RAPGEF4CA12CA1CA2CA9 | |
| SCHEMBL22858205 | 0.76 | PTGS2 (0.36) | RAPGEF4CA12CA1CA2CA9 | |
| SCHEMBL6423000 | 0.75 | TP53 (0.43) | TP53GAAALDH1A1HTT | |
| SCHEMBL4798346 | 0.75 | KMT2A (0.41) | CA12CA1CA2CA9CYP2C9 | |
| SCHEMBL16055972 | 0.75 | UTS2R (0.43) | CA12CA1CA2CA9CYP2C9 | |
| SCHEMBL16819842 | 0.75 | HSD17B2 (0.36) | RAPGEF4CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476677-B2 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1716155-B1 | SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | ASTRA ZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| EP-1716155-A1 | SUBSTITUTED THIENO¬2,3-D|PYRIMIDINES AS INHIBITORS OF TIE2 | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005075483-A1 | SUBSTITUTED THIENO - AND THIAZOLO - [2, 3-D] PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | TIE1, TEK, TEKT1 | CYP19A1 3128/4885NPY2R 102/4885RAPGEF4 4434/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | CYP19A1 1603/4885NPY2R 159/4885RAPGEF4 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.